These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35843487)

  • 1. Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID.
    Valentim CCS; Singh RP; Du W; Moini H; Talcott KE
    Ophthalmol Retina; 2023 Jan; 7(1):24-32. PubMed ID: 35843487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
    Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
    Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
    Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
    Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
    Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial.
    Hirano T; Toriyama Y; Takamura Y; Sugimoto M; Nagaoka T; Sugiura Y; Okamoto F; Saito M; Noda K; Yoshida S; Ishibazawa A; Sawada O; Murata T
    Jpn J Ophthalmol; 2021 May; 65(3):354-362. PubMed ID: 33559843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
    Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
    Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
    Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
    Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of Change in Macular Thickness With Change in Visual Acuity in Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials.
    Nanegrungsunk O; Gu SZ; Bressler SB; Du W; Amer F; Moini H; Bressler NM
    J Vitreoretin Dis; 2022; 6(4):284-289. PubMed ID: 37007927
    [No Abstract]   [Full Text] [Related]  

  • 13. INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES.
    Dhoot DS; Moini H; Reed K; Silva FQ; Berliner A; Du W; Sharma S
    Retina; 2023 Feb; 43(2):254-262. PubMed ID: 36265076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.
    Wykoff CC; Marcus DM; Midena E; Korobelnik JF; Saroj N; Gibson A; Vitti R; Berliner AJ; Williams Liu Z; Zeitz O; Metzig C; Schmelter T; Heier JS
    JAMA Ophthalmol; 2017 Feb; 135(2):107-114. PubMed ID: 28006063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
    Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
    Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema.
    Sivaprasad S; Regnier SA; Fajnkuchen F; Wright J; Berger AR; Mitchell P; Larsen M
    Adv Ther; 2016 Apr; 33(4):597-609. PubMed ID: 26951552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data.
    Ziemssen F; Schlottman PG; Lim JI; Agostini H; Lang GE; Bandello F
    Int J Retina Vitreous; 2016; 2():16. PubMed ID: 27847634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.